Aortic valve replacement: when it's needed, how the method is chosen, and what to expect after surgery

Aortic valve replacement is a procedure in which a damaged aortic valve is replaced with an artificial one. The main goal of the procedure is to restore normal blood flow from the left ventricle to the aorta and prevent the heart from further overworking. Today, it is one of the key treatments for severe aortic stenosis and some cases of severe aortic insufficiency. [1]

Modern cardiology views aortic valve replacement not as a single procedure, but as a spectrum of options. In some cases, preference is given to classic surgical valve replacement, while in others, a transcatheter approach is used, where a new valve is delivered through a vessel without fully opening the chest. The choice depends on age, anatomy, comorbidities, life expectancy, and long-term treatment strategy. [2]

In recent years, the approach to choosing a method has changed significantly. The 2025 European guidelines lowered the age threshold in favor of transcatheter replacement to 70 years for patients with a tricuspid aortic valve and suitable anatomy, while the 2020 American guidelines recommend surgical intervention primarily for patients under 65 years of age or with a life expectancy of more than 20 years, and for patients aged 65–80 years, the choice should be made after joint discussion. [3]

In practical terms, this means that today the old, one-size-fits-all formula of "one operation fits all" no longer applies. The decision-making center has become a multidisciplinary heart valve board, which evaluates not only the valve itself, but also vascular access, coronary arteries, the risk of repeat interventions, the likelihood of prosthesis size mismatch, and even future access to the coronary arteries after valve placement. [4]

What's more important for the patient is that aortic valve replacement often not only alleviates symptoms but also changes the prognosis. In people with severe, symptomatic aortic stenosis, delaying intervention is associated with worsening heart failure, syncope, hospitalization, and the risk of death, whereas timely valve replacement in appropriately selected patients typically significantly improves well-being and survival. [5]

What you need to understand right away	Practical meaning
Aortic valve replacement is not a single method, but several approaches	The choice is made individually
Main options	Surgical and transcatheter prosthetics
Main indications	Severe aortic stenosis and some cases of severe aortic insufficiency
The choice of method depends on age, anatomy and prognosis	Symptoms alone are no longer enough
The decision must be made by a valve council.	This is the standard of modern practice.

Sources for the table. [6]

When is prosthetics really necessary?

The most common indication for aortic valve replacement is severe, symptomatic aortic stenosis. When a patient experiences shortness of breath, chest pain, fainting, decreased exercise tolerance, or signs of heart failure, and examination confirms severe valve narrowing, medications do not address the underlying mechanical problem. In this situation, the valve needs to be replaced, not simply "maintained with medication." [7]

Replacement is necessary not only for stenosis but also for severe aortic insufficiency, when the valve allows blood to flow back into the left ventricle. The 2020 American guidelines specifically emphasize that in asymptomatic severe aortic insufficiency, intervention is already indicated when the left ventricular ejection fraction drops below 55%, and with progressive deterioration of left ventricular function or an increase in its size, the consideration of surgery is raised even earlier. [8]

A very important area of modern cardiology is asymptomatic severe aortic stenosis. For a long time, such patients were often simply observed, but new data have changed the picture. The 2025 European guidelines introduced a new recommendation in favor of earlier intervention in some patients with severe high-gradient stenosis, and the EARLY TAVR trial demonstrated the superiority of early transcatheter intervention over simple observation in carefully selected asymptomatic patients. [9]

It's also important to remember that the indications depend not only on the valve but also on the rest of the heart. If a patient already has reduced left ventricular contractility, has had concomitant surgery on the aorta or coronary arteries, has significant calcification, bicuspid aortic valve, or other valvular defects, the final management may differ from the standard scenario. This is why guidelines so strongly emphasize the role of team discussion. [10]

A separate practical conclusion is this: not every patient with valvular disease requires immediate valve replacement, but every patient with confirmed severe aortic valve disease and complaints should be promptly referred for expert evaluation. Delaying this procedure is dangerous because the deterioration in myocardial and organ function sometimes becomes irreversible, even if the valve itself is subsequently technically successfully replaced. [11]

When intervention is usually needed	Comment
Severe aortic stenosis with symptoms	Classic primary indication
Severe aortic insufficiency with symptoms	Surgery is often necessary
Asymptomatic severe aortic insufficiency with reduced ejection fraction	Already an indication for valve replacement
A proportion of asymptomatic patients with severe aortic stenosis	Now being considered for earlier intervention
Combination with other cardiac surgery	Tactics often become more active

Sources for the table. [12]

How to choose between surgical and transcatheter methods

Surgical aortic valve replacement remains a crucial option, particularly for younger patients, those with complex anatomy, and those requiring the most predictable long-term outcome. The 2025 European guidelines retain surgical replacement as the preferred option for patients under 70 years of age with low surgical risk, while the 2020 US guidelines maintain this option for patients under 65 years of age or with a life expectancy of more than 20 years. [13]

Transcatheter aortic valve replacement has become a viable alternative, rather than a fallback option for those "too ill." European guidelines from 2025 recommend it for patients aged 70 years and older with a tricuspid aortic valve and suitable anatomy, while American guidelines from 2020 consider it preferable for patients over 80 years of age or younger patients with a life expectancy of less than 10 years in the absence of anatomical contraindications to transfemoral access. [14]

Between these two extremes lies a large group of patients for whom there is no single "correct" answer. For those aged 65-80 in American guidelines and for many patients under 70 in European guidelines, the decision is made after discussion with the patient, weighing not only the risk of the procedure itself but also the likely longevity of the valve, the risk of re-intervention, the possibility of future access to the coronary arteries, and the likelihood of prosthesis size mismatch. [15]

Computed tomography plays a crucial role. Modern imaging helps assess valve annulus size, outflow tract calcification, the risk of coronary artery occlusion, femoral artery suitability, and anatomical features that favor surgery or, conversely, a transcatheter approach. In 2025, European guidelines effectively gave computed tomography a "guiding" role in the choice of intervention. [16]

Recent randomized data generally confirm that, with proper patient selection, both methods produce good results. In the Evolut Low Risk study, the rates of death from any cause or disabling stroke were comparable after transcatheter and surgical interventions at 5 years, and in the NOTION study, there were no differences in death, stroke, heart attack, or bioprosthesis failure after 8 years. This strengthens the case for the transcatheter method, but does not disprove surgery as the best option for some patients. [17]

A question of choice	What most often inclines one to surgery?	What most often inclines towards the transcatheter method?
Age	Younger age	Older age
Life expectancy	Longer	Briefly speaking
Anatomy	Bicuspid valve, complex ring, high risk of coronary artery occlusion	Suitable anatomy and good vascular access
Concomitant cardiac surgery	Aortic or coronary artery surgery is needed.	There is no need for open surgery
Long-term strategy	Maximum predictability for many years is important	Less invasiveness and faster recovery are important

Sources for the table. [18]

How to choose the valve itself: mechanical or biological

Even after selecting an approach, a major question remains: what type of prosthesis is needed. Mechanical valves are very durable but require lifelong therapy with vitamin K antagonists. Biological valves do not require lifelong classical anticoagulation simply because of the prosthesis itself, but they wear out over time and may require reoperation. This compromise remains central to modern valve surgery. [19]

The 2025 European guidelines generally favor a mechanical valve in the aortic position in patients under 60 years of age and a biological valve in patients over 65 years of age. The 2020 American guidelines suggest an earlier transition to individualized choice: a mechanical valve is reasonable in patients under 50 years of age, the choice should be personalized for those aged 50–65 years, and after 65 years, a biological valve is generally preferred. [20]

New research is fueling the debate, particularly in the intermediate age group. Observational data from 2025 showed that in patients 60 years and younger, a mechanical aortic prosthesis was associated with better long-term survival than a biological one, and other studies have suggested a possible advantage of mechanical prostheses even in some patients under 70 years of age. However, this does not change the fact that the actual choice still depends on the risk of bleeding, willingness to undergo lifelong monitoring of the international normalized ratio, pregnancy plans, lifestyle, and patient preferences. [21]

Biological valves are made from animal or human tissue and are particularly attractive for older patients and those for whom anticoagulation is undesirable or difficult to administer. However, biological valves have a downside: structural degeneration. Therefore, in younger patients who face decades of life after surgery, the question of reoperation should be discussed early, rather than "sometime later." [22]

For selected young patients with suitable anatomy, the Ross procedure, in which the patient's native pulmonary valve is used in place of the aortic valve, is also being considered. The 2020 American guidelines allow this option for patients under 50 who prefer to forgo a mechanical prosthesis and lifelong anticoagulation. However, this is a specialized procedure and should only be performed in experienced centers. [23]

Valve type	The main advantage	The main disadvantage	Who is it most suitable for?
Mechanical	Very high durability	Lifelong anticoagulation and the risk of bleeding	Younger patients without contraindications to anticoagulation
Biological	Fewer problems with lifelong anticoagulation due to the valve itself	Limited durability and risk of re-intervention	Older patients and people at high risk of bleeding
Operation Ross	Good hemodynamics and absence of a mechanical prosthesis	Complex specialized operation	Very selective, in some young patients

Sources for the table. [24]

Preparation for aortic valve replacement

Preparation begins with precise confirmation that the valve truly requires replacement. Echocardiography remains the primary method of initial assessment, as it reveals the degree of stenosis or insufficiency, the impact of the defect on the left ventricle, and associated valvular changes. Current guidelines recommend not limiting the diagnosis to a single number, but rather assessing the entire valve syndrome. [25]

If a transcatheter approach is being considered, the next critical step is a computed tomography scan of the heart and blood vessels. It helps measure the valve annulus, understand the shape and extent of calcification, assess the risk of coronary artery occlusion, and select the optimal vascular access. Without such a preoperative tomographic map, it is no longer possible to accurately plan the intervention. [26]

The coronary arteries, renal function, respiratory system, heart rhythm, neck and leg vessels, hemoglobin levels, and bleeding risks are assessed simultaneously. The goal of this comprehensive preoperative assessment is not to "collect more tests," but to understand in advance what could go wrong and how to make the procedure safer. This is especially important in elderly patients with frailty, chronic kidney disease, previous strokes, and multivessel atherosclerosis. [27]

Discussion in a valve center or at a valve consultation is now considered a quality standard. Both European and American guidelines emphasize that patients with severe valvular heart disease who are being considered for intervention should be assessed multidisciplinary. This reduces the risk of a patient receiving a particular center's "favorite" method instead of the truly best method for their case. [28]

Finally, home preparation is also important. Discuss teeth and gums in advance, as sources of infection should preferably be treated before prosthesis implantation. Plan home care for the first few weeks, clarify the anticoagulant withdrawal and reinstatement schedule, and understand the rehabilitation plan and timing of follow-up echocardiograms. Good preparation reduces the number of postoperative surprises as much as the quality of the surgery itself. [29]

What is included in the preparation?	Why is this necessary?
Echocardiography	Confirm the severity of the defect and its impact on the heart
Computed tomography	Select the size and installation method of the valve
Coronary artery assessment	Don't miss concomitant ischemic disease
Laboratory tests and kidney evaluation	Reduce the risk of complications
Discussion at the valve council	Choose the optimal method
Sanitation of infection foci	Reduce the risk of prosthetic endocarditis

Sources for the table. [30]

How the intervention is performed and what happens in the first days

Surgical aortic valve replacement is performed through a median sternotomy or less invasive approaches in suitable patients. During surgery, the damaged valve is removed, the valve ring is prepared, and a new prosthesis is implanted. This is a reliable and well-studied method, but it requires cardiopulmonary bypass and a longer recovery period compared to the transcatheter approach. [31]

Transcatheter valve replacement is typically performed through the femoral artery. A new biological valve is delivered via a catheter to the native aortic valve and deployed within it. Essentially, the new valve pushes the old leaflets toward the walls and begins functioning immediately. For many patients, the main advantage of this approach is less invasiveness and faster recovery. [32]

The first hours after any type of prosthetic procedure are focused on monitoring bleeding, heart rate, blood pressure, renal function, and neurological status. Surgery often requires a longer stay in the intensive care unit and drainage, whereas some patients in uncomplicated cases are mobilized more quickly after transcatheter intervention. However, the speed of discharge should still be driven by safety, not by attractive statistics. [33]

Improvement in well-being often begins quite early, but not equally for everyone. After correction of severe stenosis, pressure on the left ventricle decreases, and exercise tolerance usually improves. However, in patients with late intervention, severe diastolic dysfunction, pulmonary hypertension, or significant underlying coronary artery disease, recovery may be slower. [34]

It's crucial to understand that a "successfully placed valve" does not automatically equate to a complete recovery. After surgery, it's important to evaluate the gradients on the prosthesis, the presence of paravalvular regurgitation, the condition of the conduction system, the need for a pacemaker, and the actual improvement in symptoms. Therefore, follow-up echocardiography and clinical observation are essential even in the presence of excellent health. [35]

Stage	What usually happens
Day of Intervention	Installing a new valve surgically or through a catheter
The first hours	Monitoring bleeding, pressure, rhythm, and neurological status
The first 1-3 days	Early activation, assessment of prosthesis function
First week	Selection of medications, decision on discharge and monitoring plan
After discharge	Control echocardiography and gradual increase in load

Sources for the table. [36]

Life after surgery: medications, monitoring, restrictions

After replacement, an equally important stage begins: long-term care. The goal is to protect the new valve and prevent thrombosis, infection, structural degeneration, arrhythmia, and deterioration of the heart's pumping function. This requires medications, regular visits, and imaging tests, not just the feeling that "breathing has become easier." [37]

If a mechanical valve is installed, vitamin K antagonists are required for life. The 2020 US guidelines indicate that for modern mechanical aortic valves, the standard target international normalized ratio is typically 2.5, while for certain On-X models and in the absence of thromboembolic risk factors, a lower range of 1.5-2.0 is acceptable starting at 3 months postoperatively in combination with aspirin. Direct oral anticoagulants are not used with mechanical valves. [38]

If a biological surgical prosthesis is inserted, the postoperative antithrombotic therapy regimen is usually more lenient and individualized. The European commentary on the 2025 guidelines emphasizes that after surgical bioprostheses, early anticoagulation or antiplatelet therapy should be individualized, while after transcatheter prosthesis insertion, in the absence of a specific indication for anticoagulation, low-dose aspirin is often preferred over routine dual antiplatelet therapy. [39]

Follow-up echocardiography is mandatory. For transcatheter interventions, American guidelines recommend echocardiography approximately 30 days after surgery and then at least once a year. In practice, after any type of prosthetic procedure, a series of repeat examinations allows for the timely detection of leaflet thrombosis, increased gradients, bioprosthesis degeneration, or prosthesis size mismatch. [40]

A separate issue is the prevention of infective endocarditis. Patients with prosthetic valves are at high risk for adverse endocarditis outcomes, so recommendations for dental prophylaxis and oral hygiene are especially important for them. This does not mean constant antibiotic use, but it does mean mandatory discipline during invasive dental procedures and a very serious approach to chronic infection. [41]

Situation after intervention	What is usually required
Mechanical valve	Lifelong therapy with a vitamin K antagonist
Biological surgical valve	Individualized early antithrombotic regimen
Transcatheter bioprosthesis without other reason for anticoagulation	More often, low doses of acetylsalicylic acid
Any prosthesis	Regular echocardiography and clinical monitoring
Dental procedures	Prevention of endocarditis in high-risk patients according to recommendations

Sources for the table. [42]

Possible complications and problems

Surgical and transcatheter methods share common risks: stroke, bleeding, acute renal dysfunction, infection, valve thrombosis, endocarditis, and death. However, their complication profiles are not identical. It's important not to look for the "perfect, risk-free method," but to understand which risks are more likely for each individual patient. [43]

After surgical replacement, postoperative atrial fibrillation, more severe bleeding, and prolonged chest wall recovery are more frequently observed. After transcatheter intervention, the need for a permanent pacemaker, paravalvular regurgitation, and problems with future coronary artery access are more frequently discussed. In updated 5-year comparative data and review publications, this complication balance remains the most consistent. [44]

A separate problem is prosthesis size mismatch. This occurs when the installed valve functions technically properly, but its effective orifice area is too small for a given body size. This condition leads to higher residual gradients and can worsen the long-term prognosis, especially if the mismatch is severe. Therefore, the valve size and type should be planned in advance, rather than simply "installing whatever fits." [45]

Biological valves can degenerate over time, while mechanical valves can thrombose or bleed when treated with anticoagulation. For repeat interventions, the "valve-in-valve" strategy is increasingly being used, where a new transcatheter valve is inserted into a failed bioprosthesis. However, this solution requires very careful preoperative planning, particularly due to the risk of coronary artery occlusion and high residual obstruction with a small, old prosthesis. [46]

Prosthetic valve endocarditis remains a rare but serious complication after both methods. Long-term data show that the risk of infection after transcatheter and surgical bioprosthesis is generally comparable, but the prognosis after established prosthetic valve endocarditis remains serious. This is why follow-up monitoring and infection prevention are so important. [47]

Complication	What method is most often discussed after
Bleeding and postoperative atrial fibrillation	Surgical
Paravalvular regurgitation and pacemaker	Transcatheter
Valve thrombosis	Both methods
Structural degeneration of a bioprosthesis	Biological valves of both types
Mismatch of the prosthesis size to the patient	Both methods, especially with a small ring
Prosthetic endocarditis	Both methods

Sources for the table. [48]

Forecast and current trends

If the intervention is performed promptly and the method chosen is correct, the prognosis after aortic valve replacement is usually good. Most patients experience significant symptom relief, improved exercise tolerance, and a reduced risk of heart failure and sudden decompensation compared to the natural course of severe valve disease. [49]

For the transcatheter method, the most pressing historical issue concerned durability. Today, this situation has become much calmer. In the randomized Evolut Low Risk trial, the rate of death from any cause or disabling stroke was comparable to surgery after 5 years, and in the NOTION trial, there was no difference in clinical outcomes or bioprosthetic failure after 8 years. Structural degeneration in that trial was even less common after the transcatheter approach. [50]

Further reassurance was provided by more recent data from PARTNER 3. In 2025, the American College of Cardiology reported a 7-year low-risk follow-up study in which transcatheter and surgical valve replacement showed similar long-term outcomes and excellent valve function. However, even these data do not change the fact that in very young patients, surgery remains the mainstay of treatment due to its long-term strategy for decades to come. [51]

Another important trend is shifting intervention to earlier stages of the disease. The EARLY TAVR study and the 2025 European guidelines demonstrate that the era of "waiting until deterioration is obvious for everyone" is gradually disappearing. Now, for some asymptomatic patients with severe stenosis, intervention is being considered earlier, especially if there are signs of adverse progression and the procedural risk is low. [52]

The future of this field is not the triumph of one method over another, but increasingly precise personal selection. For one patient, the best choice will be surgical replacement with a mechanical valve, for another, a biological surgical prosthesis, for a third, a transcatheter valve, and for a fourth, a future repeat intervention using a valve-in-valve approach. This is why modern medicine is increasingly debating less about the "best in general" and more about "the best for this particular individual." [53]

What influences the prognosis the most?	Why is this important?
Was the intervention performed on time?	Late surgery results in poorer myocardial recovery.
Choosing the right method	Reduces the risk of complications and re-interventions
Type of prosthesis	Determines durability and drug load
Quality of postoperative follow-up	Allows you to notice problems in time
Associated diseases and anatomy	Affect real, not just “tabular” risk

Sources for the table. [54]

FAQ

When, after diagnosis, is it no longer possible to delay aortic valve replacement?
Delaying surgery is dangerous in cases of severe aortic stenosis with complaints, signs of heart failure, fainting, chest pain, and also in cases of severe aortic insufficiency with decreased left ventricular function. These situations are among the most compelling arguments in favor of intervention in current guidelines. [55]

Which is better: surgery or the transcatheter approach?
There is no universally superior method. In younger patients and those with complex anatomy, surgery is often preferred, while in older patients and those with suitable anatomy, the transcatheter approach is often optimal. In intermediate situations, the decision is made after a joint discussion at the valve center. [56]

Which valve lasts longer?
A mechanical valve typically lasts longer than a biological valve, but requires lifelong anticoagulation. A biological valve requires less medication but can degenerate over time. Therefore, the choice is not only a question of longevity but also a matter of lifestyle, bleeding risk, and preparedness for future interventions. [57]

Is it possible to lead an active life after prosthetic replacement?
Yes, most patients experience a significant improvement in quality of life and exercise tolerance after recovery. However, activity is resumed gradually and only after the treating team confirms the stable function of the prosthesis, the heart rhythm, and the absence of complications. [58]

Are lifelong medications necessary?
With a mechanical valve, lifelong anticoagulation is mandatory. With a biological valve, lifelong anticoagulation is usually not required solely for the prosthesis itself, but early antithrombotic therapy and subsequent medications depend on the type of procedure, the presence of atrial fibrillation, coronary artery disease, and other conditions. [59]

Is it possible to perform another intervention if the biological valve wears out?
In many cases, yes. For failed bioprostheses, repeat transcatheter intervention using the "valve-in-valve" principle is increasingly being used, but the possibility of this step is best discussed before the initial surgery, as it depends on the size of the annulus, the location of the coronary arteries, and the overall long-term strategy. [60]

Key points from experts

Fabien Praz, MD, Chair of the European Society of Cardiology 2025 Guidelines Task Force on Valvular Heart Disease, University Hospital Bern, Switzerland. His main practical thesis is that the choice between surgical and transcatheter replacement should be based on the valve consultation, anatomy, and strategy for the rest of the patient's life, and not only on the surgical risk "here and now." [61]

Michael A. Borger, MD, PhD, Chairman of the 2025 Guidelines Task Force of the European Association for Cardiothoracic Surgery, Director of Cardiac Surgery at the Leipzig Heart Center. His approach is particularly important for the surgical school: even with the expansion of the transcatheter technique, the procedure remains key for young patients, those with complex anatomy, and those requiring multiple interventions. [62]

Katherine M. Otto, MD, professor of medicine and director of the Valvular Heart Disease Clinic at the University of Washington, is one of the lead authors of the 2020 U.S. guidelines. Her thesis for practice is simple: in a patient with severe aortic valve disease, the key factors are symptoms, left ventricular function, age, life expectancy, and high-quality shared decision making, rather than mechanically following a single technological trend. [63]

Philippe Genereux, MD, director of the Structural Heart Disease Program at Morristown Medical Center and principal investigator of EARLY TAVR, added weight to the emerging idea that some patients with severe, asymptomatic aortic stenosis may benefit from earlier intervention rather than waiting until symptoms become apparent. [64]

Conclusion

Aortic valve replacement today is no longer simply a choice between a "major operation" and a "gentle method." It is a well-thought-out strategy that simultaneously considers age, anatomy, type of valve defect, the likelihood of repeat interventions, the patient's lifestyle, and readiness for long-term drug therapy. [65]

The most practical conclusion is this: the best results are achieved not by the most fashionable method, but by a properly chosen method, performed in a timely manner and at a center equally skilled in both surgical and transcatheter approaches. This is precisely what is considered modern, high-quality medicine in the field of aortic valve surgery today. [66]